Brom Podcast

Today's guests are MJ Antonini & Nicki Driscoll, the founders of NeuroBionics, a neurotech startup out of MIT. NeuroBionics is making Deep Brain Stimulation minimally invasive though the development of nano fibers that are 10X thinner than traditional Deep Brain Stimulation leads - allowing them to be inserted endovascularly into the brain. Check out NeuroBionics at https://neurobionics.io/

Can Kanna, a plant medicine from South Africa treat premature ejaculation? John Boghossian and Dr Ryan Protzko from Kanna Health are here to educate us. https://www.kanna.health/

Can brain implants treat your depression? Ok, technically this would be a skull implant, not a brain implant - but still! Jacob Robinson from Motif Neurotech discusses the future of minimally invasive electronic medicine from mental health and beyond. This is a crossover episode from the Business Trip podcast.

Why Academics & PhDs Should Consider Starting a Startup - Fireside chat with Brom Rector and Sam Tabone at the USC Neuroscience Graduate Program Retreat

Will MDMA and psychedelic therapy be affordable? There are lots of questions about the economic and financial future of psychedelic therapies. How much will they cost? Will insurance cover them? And more fundamentally, how does one even begin to quantify the value of a psychedelic experience? Today's guest, Elliot Marseille, PhD is here to explore all these questions and more. Dr. Marseille is a leading expert on the economics of the emerging psychedelic-assisted therapies. He is the founding Director of the UC Berkeley's Global Initiative for Psychedelic Science Economics (GIPSE), a network of health economists and health services researchers dedicated to realizing the potential of psychedelic therapies for high-priority mental health conditions. Through the application of policy-relevant economic analyses, GIPSE seeks to enhance the efficiency of service delivery, and increase access to these promising therapies. Follow Dr. Marseille's work: https://cghdde.berkeley.edu/projects/global-initiative-psychedelic-science-economics-gipse Brom on Twitter: https://twitter.com/therealbrom Sam on Twitter: https://twitter.com/samalanascience Brom & Sam's VC Fund: https://www.empath.vc/ Make sure to subscribe to the show!

Today's guest is Raad Seraj, Raad is a technologist, angel investor, artist, and advocate for emerging mental health therapies including psychedelics. Raad recently launched his podcast, Minority Trip Report (MTR), to discuss under-represented views and life journeys with mental health, psychedelics, and consciousness. Learn more about Raad on his website: https://raadseraj.com/about-me Listen to his podcast: https://www.minoritytrip.com/

Lack of authentic human connection is one of the biggest problems facing society. Can psychedelics deepen our relationships, strengthen our communities and help us have better sex? Dr Molly thinks that the answer just might be "Yes". In this episode: - battling the stigmas around sex and drugs - how psychedelics can improve your sex life - the risks of falling in love with an AI boy/girl friend Follow Dr Molly at https://drmolly.co/ Check out Brom's VC fund at https://www.empath.vc Make sure to subscribe to the show!

Schedule35 sells psilocybin mushrooms online in the US and Canada (yep, you heard that right). Their branding is amazing and they advertise on mainstream podcasts like Hotboxin' with Mike Tyson - where I first heard of them. Leon, the founder of Schedule35 joins Brom today to tell us: - how he got into microdosing and started Schedule35 - what it takes to run an online psilocybin business in the current regulatory environment - his views on pharma / medicalized psychedelics VS recreational psychedelics Make sure to subscribe to the show! Check out Schedule35 at schedule35.co Check out Brom's VC fund at empath.vc

The Brom Podcast covers the emerging psychedelics industry from a business, investing and social impact perspective. Episodes feature Empath Ventures' Founder, Brom Rector interviewing psychedelic CEOs, scientists, investors, and other change-makers operating in the weird, wonderful world of psychedelic medicine. The Brom Podcast is available on all platforms! Music from Uppbeat (free for Creators!): https://uppbeat.io/t/sky-toes/desert-flower License code: JIRV6GGWC28YEPJH

Rebecca Nicholson is the CEO of 5D World and Founding partner of 5D Ventures. Unlike other psychedelic VCs that focus on biotech, 5D's “Progression of Consciousness Fund” is the only psychedelic fund focused on investing in psychedelic retreats. Rebecca joins the Brom podcast to discuss: - her views on investing in retreats - the difference between retreats and clinics - her own experience at some of these retreats - including tripping with Amanda Feilding - the importance of the feminine perspective in the psychedelic industry. Make sure to subscribe to the show! Check out 5d world at: https://www.5dworld.com/ Follow Brom on Twitter: https://www.twitter.com/therealbrom Brom's Venture Fund: https://www.empath.vc

Zach Haigney is the author of The Trip Report, a newsIetter that covers the emerging psychedelic science, medicine, and policy landscape. In this conversation, Zach and Brom discuss emerging trends, questions and hot topics in the psychedelics industry including: The lines of tension between Drug Development and Drug Policy Directive vs Non-Directive Psychedelic Therapy How Psychedelics are inverting the traditional drug development model What business models will emerge in psychedelics? Are fears about VC investment in psychedelics overstated? How psychedelics can be thought of as a form of hormetic therapy What can psychedelics be used for outside of treating mental health issues? We also discuss The Trip Report's recent acquisition by Beckley Waves. You can check out The Trip Report here: https://thetripreport.substack.com/ Follow Zach on Twitter: https://twitter.com/zach_haigney Follow Brom on Twitter: https://twitter.com/therealbrom Make sure to subscribe to the show!

Sam Banister is a medicinal chemist and co-founder of Psylo. Psylo is an Australian psychedelic biotech company using machine learning assisted drug design techniques to developing novel psychedelic medicines to treat mental illness. Sam is here to help us understand how new chemical entities are reshaping the psychedelic field; how novel psychedelic molecules are made, and how new chemical entities are going to play a dominant role in the future of psychedelic medicine. Make sure to subscribe to the show! Follow Brom on twitter: https://twitter.com/therealbrom Follow Sam on twitter: https://twitter.com/samuel_b_phd Brom's VC Fund: https://www.empath.vc Highlighted Timestamps: 06:12 - Are next generation psychedelics taking over in 10 years? 16:10 - What is the process like for creating a new chemical entities? 50:39 - Psychedelics vs Cannabis: New drug discoveries

Patrick Moher is the President of Microdose.buzz, the leading psychedelic industry website. He joins Brom today to discuss his personal history with psychedelics, his views on the future of the industry, what it was like talking about psychedelics at Davos, and gives us a preview of what's to come at Wonderland Miami 2022. Tickets for Wonderland Miami 2022 are on sale now: https://tickets.microdose.buzz/attendance/event/index/41737/EN

Mendel Kaelen is the CEO of Wavepaths. Prior to founding Wavepaths, Mendel Kaelen worked as a PhD and postdoctoral neuroscientist at Imperial College London since 2012, where his research was the one of the first to demonstrate music's central role in psychedelic therapies. Wavepaths is a software platform that generates personalized, optimal music for psychedelic therapy. 0:00 - Why work on music and psychedelics? 3:30 - Highlights of Mendel's academic career. 7:30 - Is there a universal “best” music for psychedelic therapy? How to design a psychedelic therapy playlist. 11:30 - What does the importance of music personalization mean for group psychedelic sessions? 16:00 - Should music for psychedelics be “familiar” to the patient, or novel? 20:00 - Vocals vs no vocals? It's not that simple. 23:00 - Directive vs non-directive and concrete vs fluid music. 25:00 - Is the “right” music for psychedelics consistent across different drugs? 28:00 - How did Mendel switch from academia to startup founder. 30:30 - What is Wavepaths? 35:30 - Who is Wavepaths for? 37:00 - How do you sell music for psychedelic therapy? 39:00 - Surprising insights from Wavepaths customers? 43:30 - How does Wavepaths use biofeedback? 46:00 - Wavepaths direct to consumer. 49:45 - Startup life vs academia. 51:00 - Virtual reality and psychedelic therapy.

tmp

Joe Moore is the CEO & Co-Founder of Psychedelics Today - the largest and longest running podcast and media operation in psychedelics. In this episode, Joe and I discuss the hottest topics in psychedelics: Joe Rogan, the dark forces at work in the psychedelics industry, the problem with decriminalization and amongst many other things, we speculate on how fermentation could put the drug cartels out of business (cocaine kombucha anyone?). And of course, we touch on Psychedelics Today's new training program - Vital: https://www.vitalpsychedelictraining.com/ This is an episode you don't want to miss. Joe earned a B.A. at Plymouth State University in Philosophy and has been studying psychedelics since 2001. After working for 20 years in software, Joe is dedicated to working towards improved drug policy and greater inclusion of psychedelics in culture. In 2016, Joe co-founded Psychedelics Today, a world-leading psychedelic education and media platform. The popular Psychedelics Today podcast has been downloaded over 2.4-million times, and the Psychedelics Today Psychedelic Education Center has enrolled over 9,000 students in psychedelic training e-learning courses.

Tom Feegel is the Founder and CEO of Beond. Beond exists to help end the opiate addiction epidemic with safe ibogaine treatment. In this episode Tom speaks on the severity of the opioid epidemic and explains how ibogaine assisted therapy can help heal those who are suffering from addiction. Tom gets into his personal story, how Ibogaine helped someone in his family, the economics of addiction treatment and Beond's plans to scale into a global operation. ➡️ Follow Beond: https://www.beond.us

Mycrodose's CEO Chad Conner and CSO Frank Kochinke return to the podcast to tell us about: Mycrodose's partnership with Thorne How kavalactones could be used for smoking cessation and weight loss Mycrodoses DEA license to cultivate psilocybin mushrooms And more! ⭐️ Follow Mycrodose: https://mycrodosethera.com/

Dillan DiNardo is the CEO of Mindstate Design Labs - a preclinical-stage biotechnology company developing the next generation of psychedelic-inspired therapeutics for intractable mental health conditions. Mindstate's mission is to map the biological basis of the varieties of psychedelic experience, and to use that map to pharmacologically design therapeutic states of mind to be applied in medically supervised settings to heal the root causes of mental health disorders. Mindstate participated in Y Combinator in 2021. Brom's Psychedelic VC fund, Empath Ventures is an investor in Mindstate. Check out Mindstate @ https://www.mindstate.design/

Mental health treatment is often inaccessible, inadequate, and ineffective. However, Nue Life is working to change this through its 360-degree approach to patient health, leveraging ketamine and the integration of tech. Check out Nue.Life here: https://nue.life/ ⏰ Timestamps: 0:00 intro and Juan Pablo's backstory 5:30 how Nue Life got started 11:00 the Nue Life patient experience 20:40 the intersection of data and mental health 32:30 competition in the Ketamine landscape 37:00 is ketamine addictive? 45:00 the future of at-home ketamine and the Ryan Haight act 49:15 legal psilocybin in Oregon? 53:30 what's next for Nue Life?

Eesmyal Santos-Brault & Dr. Pamela Kryskow from Quantified Citizen talk about Quantified Citizen the app, and the results of Quantified Citizen's first study: Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers. Check out the paper here: https://www.nature.com/articles/s41598-021-01811-4

The Integration Conversation is BACK with Nadia van der Heyden, Director of Sales and Marketing at Psygen. Recorded at Wonderland Miami.

Brom discusses 10 interesting startup ideas for entrepreneurs in the psychedelics space. The ideas include applications of psychedelics to non mental health disorders, sexual disfunction, anti-aging, digital addiction, crypto, non-5ht2a drugs, gender specific issues, sustainable manufacturing and digital therapeutics. If you're an entrepreneur working on a psychedelic startup, we'd love to hear from you. Please contact us at hello@empath.vc

Mycrodose Therapeutics is a US-Based pharmaceutical company specializing in the development of Advanced Drug Delivery (ADD) systems for psychedelic compounds. In this episode of The Integration Conversation, Mycrodose's Chad Conner and Patrick Eckstrom join Brom to discuss how ADD systems can potentially improve the patient experience, increase the safety profile and lower the cost of psychedelic drugs.

Todd Shapiro is the CEO of Red Light Holland ($TRIP, $TRUFF), the only publicly traded company focused on recreational psychedelics. In this episode of The Integration Conversation, Todd explains the history of Red Light Holland, speculates on timelines for when Red Light Holland will be able to sell in the US, and tells us about Red Light Holland's foray into Virtual Reality and consumer products like the Wisdom Truffle. And of course, we ask the big question: Is Red Light Holland Undervalued? --- ❤️ Invest in Brom's Psychedelic Venture Capital Fund: https://www.empath.vc

Negev Capital is a VC fund focused on psychedelic medicine. In this episode of The Integration Conversation, Ken Belotsky and Stuart Seidman tell us about Negev's founding, its strategy, and what it's like to run a venture fund in the psychedelics space. ❤️ Help us fund the future of psychedelic medicine at Empath Ventures: https://www.empath.vc ⭐️ Become an Integration Insider and get early access to episodes: https://patreon.com/theintegrationco

Jack Swain is the Head of Clinical Operations at Mindbloom, the world's largest telemedicine based ketamine clinic. In this episode of The Integration Conversation, Jack talks about what it's like to be involved in a rapidly growing psychedelic startup, the differences between in-clinic and telemedicine based ketamine therapy, and how Mindbloom will scale to other psychedelic drugs like psilocybin and MDMA. ❤️ Help us fund the future of psychedelic medicine at Empath Ventures: https://www.empath.vc

Paul Kohlhaas is the cofounder of Molecule ( https://molecule.to/ ) a collaborative platform where stakeholders in drug development work together to accelerate the process of bringing novel therapeutics to patients. He is also the co-initiator of VitaDAO ( https://www.vitadao.com/ ), a decentralized collective funding early stage longevity research. In this episode we discuss the exciting intersection of crypto and biotech, and how DAOs might replace some of the traditional funding mechanisms of scientific research. ❤️ Help us fund the future of psychedelic medicine at Empath Ventures: https://www.empath.vc

Bruce Linton is a legend in the cannabis and psychedelics industries. He was the CEO of the world's largest cannabis company (Canopy Growth), was the first investor in MindMed, and is Chairman of the Advisory Board at Red Light Holland. Bruce joins The Integration Conversation to answer questions like: Why did Bruce Linton sell shares in MindMed? Why did JR leave MindMed? What's the difference between paid promotion & pump and dumps? Are psychedelics just cannabis 2.0? And more! Plus, Brom and Bruce talk about Empath Ventures. ❤️ Help us fund the future of psychedelic medicine at Empath Ventures: https://www.empath.vc ⭐️ Become an Integration Insider and get early access to episodes: https://patreon.com/theintegrationco

What exactly is psychedelic therapy, and what does the research on psychedelic therapy tell us about its effectiveness? In this episode of The Integration Conversation, Brom provides a description of what exactly happens during psychedelic therapy, and then goes over the three most compelling clinical research papers on psychedelic therapy. Learn about how MDMA can treat Post Traumatic Stress Disorder, psilocybin can treat depression, and how psilocybin stacks up against SSRIs like Lexapro.

In this episode of The Integration Conversion, brom give a broad overview of the psychedelic investing landspace, and addresses come common misconceptions about investing in psychedelics. Topics Include: What does "investing in psychedelics" actually mean? How big could the psychedelics market get? What problems are psychedelics solving? What are the different sub-segments of the psychedelic industry Why is now the right time to get involved in the psychedelics industry? Won't decriminalization destroy profits? Aren't psychedelics just cannabis 2.0? We answer these questions and more - enjoy

I'm experimenting with a weekly livestream format where I respond to short psychedelic articles / topics that don't warrant an entire video. Plus I interact with the viewers and answer their questions about any psychedelic topics.

Atai Life Sciences is the most highly anticipated psychedelic IPO of 2021. It has a pipeline of 10 drugs, owns a large piece of Compass Pathways, and is also researching digital therapeutics and brain computer interfaces. When it IPOs it will likely be the psychedelic company with the largest market cap. In this episode of Brom Talks, we peek behind the curtain of Atai, and try to see if this valuation is justified. In doing so, we answer questions like: Who is Christian Angermayer? What does Atai's pipeline look like? What are the implications of Atai's unorthodox corporate structure? It is even fair to call Atai a psychedelics company? And we also compare and contrast this company with MindMed.

What is the true market cap potential for the medicinal psychedelic industry, and what's the best way to ride the shroom boom and invest in the psychedelic sector? I show three different market cap estimates, discuss various pitfalls and caveats, and give my thoughts on how best to invest in this space. Watch the video: https://youtu.be/jb949AKsYAA

Today we go deep into Numinus Wellness. Numinus (also known as Numi) is a Canadian Psychedelic startup that many people think is undervalued. This episode looks into this claim and tries to answer questions like: Who is Numi's team? Is Numi's natural psilocybin superior to synthetic psilocybin? Why is Numi's market cap so low compared to the leading psychedelic companies? What's the deal with Numi's MAPS collaberation? Can Numi (or any other company) make money running psychedelic clinics? You can watch this episode on YouTube https://youtu.be/jg2H0sMHZXg See Brom's other links https://linktr.ee/therealbrom Disclaimer: This video is not financial advice. Do you own research before buying or selling any stock, and talk to a financial advisor whos incentives are aligned with your own. Brom owns shares of Numi as well as other psychedelic companies.

This is part two of my MindMed Deep Dive. The primary focus of this video is an analysis of MindMed's acquisition of HealthMode. I also clear up a few things from the last video. Did the HealthMode acquisition make sense for MMED? What are their true AI / ML capabilities? Did I sell any shares after the last video? Clarification on my opinion on Departures Capital. Watch the video here: https://youtu.be/LUnEIRZmegE Part 1 is here (https://youtu.be/cfqdvm_Bz-w​).

Many of us have already 10x'd our money on MindMedicine (MMED / MMEDF): should we take our profits now or hold for the next 10 years? Brom dives deep into this topic and looks at questions like: Will the Nasdaq uplisting happen? Is MindMed's drug development pipeline strong? Why is MindMed associated with sketchy pump and dump groups like Departures Capital and Market Jar Media? Do they have a way to capitalize on their research? WTF is Kevin O'Leary doing in a drug company? Why did JR Rahn sell his shares? Does MindMed Founder and CEO JR Rahn have the right qualifications? Is MindMed's team a winning team? Watch on YouTube https://www.youtube.com/playlist?list=PLSojjMXxr79FMrXF5ocZ5Qy5uEQ78FQJG Listen to this video on Spotify: https://open.spotify.com/show/1nVnMFaYNmln6fwk63B9kd Listen to this video on other Podcast Platforms: https://anchor.fm/brom1 Brom on Instagram: https://www.instagram.com/brom_qr/channel/ Brom on Twitter: https://twitter.com/therealbrom Brom's personal website: https://brom.ai

We talk the future of psychedelics: decriminalization & legalization. Biotech & Pharma research, Compass Pathways (CMPS), Mind Medicine (MMED / MMEDF), Field Trip Health (FTRP) on substances like LSD, Psilocybin, Ibogaine, etc.